Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial


Petrylak D. P., de Wit R., Chi K. N., Drakaki A., Sternberg C. N., Nishiyama H., ...More

LANCET ONCOLOGY, vol.21, no.1, pp.105-120, 2020 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.1016/s1470-2045(19)30668-0
  • Journal Name: LANCET ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.105-120
  • Inonu University Affiliated: Yes

Abstract

Background Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonistplus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary endpoint of overall survival results for the RANGE trial.